Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $152.50 short put and a strike $147.00 long put offers a potential 31.26% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $152.50 by expiration. The full premium credit of $1.31 would be kept by the premium seller. The risk of $4.19 would be incurred if the stock dropped below the $147.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is at 30.79 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Stocks That Fell to 3-Year Lows in the Week of Nov. 30
Sat, 01 Dec 2018 22:53:20 +0000
Allergan PLC (ACT), Schlumberger Ltd. (SLB), General Mills Inc. (GIS) and Noble Energy Inc. (NBL) have declined to their 3-year lows
EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?
Fri, 30 Nov 2018 17:30:00 +0000
EyeGate (EYEG) announced Q3 financial results and provided a business update. To-date, EYEG has received $13.8M in upfront and milestones under the two agreements, including ~$300k in the most recent quarter. While the yoy decrease reflects a change in activity from the relatively large EGP-437 trials to the smaller OBG studies, the qoq increase is a result of continued progression of both OBG programs.
Recent Analysis Shows Applied Optoelectronics, J.M. Smucker, RYB Education, Inc. Sponsored ADR, Workiva, Bilibili Inc. Sponsored ADR, and Allergan plc Market Influences — Renewed Outlook, Key Drivers of Growth
Fri, 30 Nov 2018 13:20:00 +0000
NEW YORK, Nov. 30, 2018 — In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
A Pharmaceutical Company With a Resilient Portfolio and Solid Pipeline
Thu, 29 Nov 2018 22:28:57 +0000
Allergan PLC (AGN) is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva Pharmaceutical Industries Ltd. (TEVA).
A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018
Thu, 29 Nov 2018 12:30:02 +0000
On December 22, 2015, Celgene (CELG) issued a press release announcing the settlement of patent litigation for Revlimid with Natco Pharma, Arrow International, and parent company Watson Laboratories, which was then a wholly owned subsidiary of Allegan (AGN). Currently, Watson Laboratories is a part of Teva Pharmaceuticals (TEVA).
Also on Market Tamer…
Follow Us on Facebook